Argenica Therapeutics Ltd has released a press release.
Non-Dilutive Funding Received to Progress Alzheimers Studies
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers
- Argenica Awarded $1.2m CRC-P Grant for TBI Project
- Successful Completion of Phase 1 Clinical Trial Dosing
- SRC Approves Commencement Of Fourth And Final Cohort Dosing
- Phase 1 Clinical Trial Progress Update
Later from Argenica Therapeutics
- Interim Phase 1 Safety Report Confirms Safety of ARG-007
- Significant Non-Dilutive Funding For Preclinical HIE Studies
- Latest Preclinical HIE Study Results
- Final Phase1 Clinical Trial Report
- Argenica Successfully Completes $4.0m Placement
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics